48results about How to "Little or no activity" patented technology

The present invention relates to new pneumococcal vaccines. The invention also relates to vaccination of subjects, in particular immunocompromised subjects, against pneumococcal infections using said novel pneumococcal vaccines.

An automatic dishwashing detergent composition in unit dose form wherein the composition comprises at least about 0.2 mg of active starch degrading enzyme per gram of composition and wherein the weight of the composition is less than about 25 grams.

The invention provides liposomal particle compositions, which incorporate a lipophilic biodegradable polymer, such as amino acid-containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU), throughout the particles to stabilize the composition for in vivo delivery in of an incorporated biologic agent. For oral delivery, a biologic, such as insulin, is conjugated directly to the polymer. Lipids in the particle are selected to further stabilize the composition during fabrication and digestion, providing sustained delivery of the biologic with native activity. Methods of making and using the invention compositions to administer the biologic agent in vivo are also included.

The present invention relates to xyloglucanases belonging to family 44 of glycosyl hydrolases and having a relative xyloglucanase activity of at least 30% between pH 5 and pH 8 are derived from the genus Paenibacillus, especially from a strain of Paenibacillus polymyxa or Paenibacillus sp. The xyloglucanases exhibit high performance in conventional detergent compositions.

A method and apparatus implement time compression and expansion of audio data, with dynamic tempo change during playback. Dynamic changes in tempo are implemented at specific points in the audio signal corresponding to local minimums in the fade-in and fade-out characteristics of the compression / expansion scheme. An audio signal is marked to define temporal slices of audio data. Mark positions may be selected to minimize significant transient activity midway between consecutive marks. Fade-in and fade-out functions are associated with the leading side and trailing side, respectively, of each mark, creating a series of cross-fading “mounds” with peaks at each mark. When a tempo change is requested (e.g., a user selects a new tempo value in a user interface), the tempo change is delayed until the start of the next “mound” (i.e., the next fade-in). Thus, despite the tempo change, each mound uses a contiguous set of audio data, preventing the clicks and pops associated with skips in the audio data. Cross-fading minimizes any effects of desynchronization caused by overlapping mounds of differing speeds.

A method of treating cancer, inflammatory disease or an infectious disease or condition in a subject in need of such treatment is disclosed. The method comprises administering to a subject an effective amount of a manzamine, or a rationally modified manzamine derivative or analog or an optical isomer or racemate or tautomer thereof or a pharmaceutically acceptable salt or prodrug thereof generated through optimized fermentation of a Micromonospora sp., extraction from sponges and then modified through semisynthesis.

Poling structures and methods utilizing an electrostatic field generated from a polar dielectric material, including pyroelectric and ferroelectric materials, to produce electro-optic activity in organic nonlinear optical materials.

A method and apparatus are used to compare in real-time an intended radiation treatment plan with a delivered plan. Markers are arranged, on a subject receiving radiation, at three-dimensional (3D) positions between a two dimensional radiation detector and a radiation source and are used to reconstruct the actual position of a high dose rate (HDR) source in three-dimensional (3D) space. The detected position is compared with the intended radiation path of the treatment plan. Adjustments can be made to the treatment plan if the detected position and the intended path do not correspond.

The invention provides specific binding members (e.g., antibodies or antigen-binding fragments thereof) which bind to RANKL originating from multiple species. An epitope recognized by the specific binding members can be selected from surface exposed loop domains that bind to and activate its cognate receptor, RANK (Receptor Activator of NFkB), on the surface of osteoclast precursors and other cell types. The invention provides peptides for generating such anti-RANKL antibodies, including murine sequences, other non-human sequences and cross-reactive peptides. The specific binding members are useful in the diagnosis and treatment of lytic bone diseases, including osteoporosis, rheumatoid arthritis, bone metastasis and hypercalcemia of malignancy, glucocorticoid-induced bone loss, a periodontal disease or condition, a cancer and Juvenile Paget's Disease. The binding members can also be used in therapy in combination with chemotherapeutics or anti-cancer agents and / or with other antibodies or antigen-binding fragments thereof.

This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1),wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer compositionsaid units of flavan-3-ol being bonded each other in any one of three patterns as follows;(i) a bond between carbon at the position 4 and carbon at the position 8,(ii) a bond between carbon at the position 4 and carbon at the position 6,(iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon at the position 2 and oxygen at the position 7.

The present invention provides a novel psicose epimerase derived from Flavonifractor plautii and capable of converting fructose to psicose. The novel psicose epimerase according to the present invention possesses an activity producing psicose by epimerizing the carbon-3 position of fructose, and has maximal activity for the conversion of fructose to psicose at a relatively high temperature and a pH less than or equal to neutral, has excellent thermal stability, and can mass-produce psicose from fructose in a high yield for a short amount of time. Therefore, the psicose epimerase according to the present invention is advantageous in the industrial production of psicose, and it is expected that the psicose produced thereby can be usefully utilized in the functional sugar industry and also as materials for health food, medicine, cosmetics, and the like using the psicose.

Novel peptoid oligomers are disclosed that have a formula represented by the following formula I:wherein R1 and n are as described herein. The peptoids demonstrate antimicrobial and antimalarial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial or malarial infection is involved. The present cyclic peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

An acoustic guiding system of this invention comprises: an n-phase signal wiring which contains n wire lines and a common ground where n is an integer larger than or equals to three; a sound source which generates an electric current for a signal sound; a distributer which distributes the electric current from the sound source to each line of the n-phase signal wiring repeatedly; a controller which controls the signal sound in accordance with signal information required for traffic control or the like; and speakers connected to each line of the n phase signal wiring in the order of the phase number.

A 23 amino acid peptide, AtPtpl, plays an important role as a signaling component of the innate immune system of Arabidopsis. The peptide precursor gene is transcribed in response to elicitors generated by pathogens, and AtPep1 is produced to amplify the signaling pathways. Seven paralogs of the AtproPep1 gene have been identified in the Arabidopsis genome, and orthologs have been identified in species of several agriculturally important families. AtPcpl and its paralogs and orthologs play important roles as endogenous signals to amplify innate immunity. The sequence of two AtPep1 receptors from Arabidopsis are also provided.

The present invention relates to compounds (e.g. antibodies) that specifically bind and inhibit NKp46. Such compounds are capable, when administered to a mammal, capable of increasing the frequency of reactive and / or active NK cells. The invention also relates to pharmaceutical composition and methods of using the antibodies and compositions to treat or prevent diseases, e.g. cancer, infection, autoimmune diseases, inflammatory diseases and the like.

The present invention relates generally to enzyme assays and more particularly to a rapid, sensitive, reliable and robust homogeneous assay for acetyl CoA carboxylase activity comprising a coupled enzyme assay in a scintillation proximity format suitable for high-throughput screening. In one aspect, the assay couples ACC and FAS and the product, palmitic acid is then detected by scintillation counting. The invention also relates to the identification of modulators of ACC activity.

The present invention relates to a medium composition comprising fermented Korean hot pepper paste, undiluted solution of brewed soy sauce or acid hydrolyzed soy sauce, and a method for producing gamma-aminobutyric acid (GABA) using the medium. More precisely, the present invention relates to a medium composition for culturing lactobacillus having GAD activity, the composition comprising fermented hot pepper paste, brewed soy sauce or acid hydrolyzed soy sauce, and a method for producing a high concentration of gamma-aminobutyric acid from the medium additionally added with glutamic acid or glutamate. The present invention provides a method of producing a high concentration of gamma-aminobutyric acid using the above medium with low production costs. Since the by-products of pastes are used as medium compositions, this medium itself can be added to other pastes or foods to produce functional foods containing gamma-aminobutyric acid.

Catalysts for hydrogenation of CO2 to dimethyl ether. These catalysts comprise 0.1-10 wt % per total catalyst weight of a catalytic material containing Pd (e.g. metallic palladium), 0.05-5 wt % per total catalyst weight of a promoter containing Ca (e.g. metallic calcium), as well as 85-99 wt % of CeO2 as a catalyst support. Methods of preparing and characterizing the catalysts as well as processes for catalyzing the hydrogenation of CO2 to dimethyl ether and other byproducts such as methanol, carbon monoxide, and methane portrayed by reactant conversion., product selectivity, and catalyst stability are disclosed.

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases through Renin Angiotensin System (RAS) and Sympathetic System (SS). Alkylated histamine based double action Saltans are lipophilic and can act transdermally.

Novel peptoid oligomers are disclosed that have a formula represented by the following formula I:wherein R1 and n are as described herein. The peptoids demonstrate antimicrobial and antimalarial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial or malarial infection is involved. The present cyclic peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

A method and apparatus are used to compare an intended treatment plan using a radiation source with a delivered plan. This done by arranging markers at known three-dimensional (3D) positions in a detection reference system between a two dimensional radiation detector configured to acquire images generated by radiation emitted by the radiation source and an area where the radiation source is positioned during a treatment. The positions of projections of the markers on an image detected are determined when the radiation source is at a treatment position in an intended treatment plan reference system. A plurality of lines in the detection reference system are calculated, each line being defined by a 3D position of a marker and a 3D position of a corresponding projection of the marker on the detector according to the image. A 3D position of the radiation source in the detection reference system is inferred based on the calculated lines. If no correspondence between the detection reference system and the intended treatment plan reference system is available, the inferred 3D position is matched with the treatment position to extract the correspondence between the detection reference system and the an intended treatment plan reference system. If the correspondence between the detection reference system and the an intended treatment plan reference system is available, the inferred 3D position is compared with the treatment position.

The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2′,3′,5′-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.

Disclosed is a method of big data product customization and data provider's profits sharing. The method comprises the following steps: receiving a consumption microdata, verifying whether the consumption microdata conforms to a specified data format, and storing it in a personal microdata account; classifying the consumption microdata according to a predetermined classification code; and evaluating the consumption microdata to give an interests value, and storing the interests value in a personal interests account.

The present invention provides a novel psicose epimerase derived from Flavonifractor plautii and capable of converting fructose to psicose. The novel psicose epimerase according to the present invention possesses an activity producing psicose by epimerizing the carbon-3 position of fructose, and has maximal activity for the conversion of fructose to psicose at a relatively high temperature and a pH less than or equal to neutral, has excellent thermal stability, and can mass-produce psicose from fructose in a high yield for a short amount of time. Therefore, the psicose epimerase according to the present invention is advantageous in the industrial production of psicose, and it is expected that the psicose produced thereby can be usefully utilized in the functional sugar industry and also as materials for health food, medicine, cosmetics, and the like using the psicose.

This invention provides an agent for inhibiting production of hepatitis C virus with notable anti-HCV activity and without side-effects. The agent comprises a proanthocyanidin polymer composition illustrated in the following the general formula (1),wherein R1 is hydrogen or hydroxyl, R2 is hydroxyl, R3 is hydrogen when R1 is either hydrogen or hydroxyl, but R3 is possibly hydroxyl when R1 is either hydrogen or hydroxyl to the extent that both R1 and R3 being hydroxyl is at most 40 percents in the proanthocyanidin polymer compositionsaid units of flavan-3-ol being bonded each other in any one of three patterns as follows;(i) a bond between carbon at the position 4 and carbon at the position 8,(ii) a bond between carbon at the position 4 and carbon at the position 6,(iii) a bond between carbon at the position 4 and carbon at the position 8, and between carbon, at the position 2 and oxygen at the position 7.

An acoustic guiding system of this invention comprises: an n-phase signal wiring which contains n wire lines and a common ground where n is an integer larger than or equals to three; a sound source which generates an electric current for a signal sound; a distributer which distributes the electric current from the sound source to each line of the n-phase signal wiring repeatedly; a controller which controls the signal sound in accordance with signal information required for traffic control or the like; and speakers connected to each line of the n phase signal wiring in the order of the phase number.